OVdialogue – consider joining our team in the role of Community Champion. Over a few hours each week, you would be part of a team that helps connect people, support conversations and are thought leaders for OVdialogue. This is your opportunity to give back to those who have/continue to support you through the tough times, share your unique experiences, and help celebrate successes. For more details of what this entails, please reach out to @Mfallis (mfallis@ovariancanada.org).
Stay tuned for more details, and feel free to share your thoughts below. Let’s make this community even stronger!
Research study: Looking for participants
This is to inform you of a research study about ovarian cancer maintenance therapy in Canada. This study is conducted by Broadstreet HEOR on behalf of GlaxoSmithKline (also called “GSK”). GSK is a company that discovers and makes vaccines, medicines, and other healthcare products. Ovarian Cancer Canada is committed to driving research forward, and therefore shares relevant research opportunities with those affected by ovarian cancer, where appropriate.
We want to share news of a new research study that you, or someone in your family, may be interested in. The purpose of this study is to better understand the treatment preferences of people with ovarian cancer who have been eligible for PARP inhibitor maintenance therapy following chemotherapy.
Who is eligible to participate?
To participate you need to:
- Be 18 years of age or older;
- Have access to a laptop, desktop computer or tablet;
- Have received ovarian cancer treatment in Canada (e.g., chemotherapy, radiation, surgery);
- Be fluent in English or French;
- Have completed a course of chemotherapy to treat the ovarian cancer after diagnosis (also known as front-line chemotherapy);
- Have been eligible for PARP inhibitor maintenance monotherapy upon completion of chemotherapy;
- Be starting on, currently on, or previously on, niraparib (Zejula) or olaparib (Lynparza) maintenance therapy, OR decided to be closely monitored by their doctor without taking a PARP inhibitor (active surveillance);
- Have not started a new line of chemotherapy after niraparib (Zejula) or olaparib (Lynparza) maintenance therapy or active surveillance (close monitoring);
- Have not had a recurrence of ovarian cancer (i.e., the cancer has not returned after front-line treatment).
What is involved?
If you are eligible to participate in the study, we will invite you to complete an online survey. You will either complete the online survey on your own or on a virtual call with a member of the research team. This study will take about 30 minutes to complete, and you will be paid $40 for your time and insights through either an e-transfer or an Amazon gift card.
Your participation in this survey will be kept private, and you will not be identifiable from the research in any way.
More information:
If you are interested in participating, please email ovariancancerstudy@broadstreetheor.com.
Thank you for considering collaborating in this important study!